Gilead Sciences
Pharmaceutical & Health Products · Lobbying Client
C
Influence Score
51/100
Moderate Influence
$14.4M
Total Lobby Spend
4
Policy Issues
6
Lobbyists
1
Revolving Door
Gilead Sciences reported $14.4 million in federal lobbying expenditures as disclosed in Senate LDA filings. The organization's lobbying activity spans 4 policy areas, with primary focus on Health Issues, Pharmacy, Medical/Disease Research. This data is drawn from quarterly disclosure reports filed with the Secretary of the Senate under the Lobbying Disclosure Act of 1995.
Annual Lobbying Spend
Policy Issues
Government Entities Contacted
Office of Management & Budget
Dept of Interior
Dept of Homeland Security
Dept of State
Federal Trade Commission
Dept of Health & Human Services
Food & Drug Administration
Recent Filings
| Period | Registrant | Issues | Lobbyists | Amount |
|---|---|---|---|---|
| 2020 Jan-Mar | Squire Patton Boggs LLP | PHAGOVHCR+1 | 3 | $471K |
| 2020 Apr-Jun | Cassidy & Associates LLP | HCRPHAGOV+1 | 3 | $727K |
| 2020 Jul-Sep | BGR Group LLP | PHAHCRGOV | 4 | $718K |
| 2020 Oct-Dec | Holland & Knight LLP | GOV | 3 | $455K |
| 2021 Jan-Mar | Squire Patton Boggs LLP | GOV | 1 | $625K |
| 2021 Apr-Jun | Akin Gump LLP | HCRMED | 4 | $778K |
| 2021 Jul-Sep | Cassidy & Associates LLP | HCRPHAGOV | 4 | $692K |
| 2021 Oct-Dec | Squire Patton Boggs LLP | HCR | 3 | $663K |